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Research Article

Diabetes induced by gain-of-function mutations in the Kir6.1 subunit
of the KATP channel
Maria S. Remedi,1,2,3 Jonathan B. Friedman,2 and Colin G. Nichols2,3
Department of Medicine, 2Department of Cell Biology and Physiology, and 3Center for the Investigation of Membrane Excitability
Diseases, Washington University School of Medicine, St. Louis, MO 63110

Gain-of-function (GOF) mutations in the pore-forming (Kir6.2) and regulatory (SUR1) subunits of KATP channels
have been identified as the most common cause of human neonatal diabetes mellitus. The critical effect of these
mutations is confirmed in mice expressing Kir6.2-GOF mutations in pancreatic β cells. A second KATP channel
pore-forming subunit, Kir6.1, was originally cloned from the pancreas. Although the prominence of this subunit in the vascular system is well documented, a potential role in pancreatic β cells has not been considered.
Here, we show that mice expressing Kir6.1-GOF mutations (Kir6.1[G343D] or Kir6.1[G343D,Q53R]) in pancreatic β cells (under rat-insulin-promoter [Rip] control) develop glucose intolerance and diabetes caused by reduced insulin secretion. We also generated transgenic mice in which a bacterial artificial chromosome (BAC)
containing Kir6.1[G343D] is incorporated such that the transgene is only expressed in tissues where Kir6.1 is
normally present. Strikingly, BAC-Kir6.1[G343D] mice also show impaired glucose tolerance, as well as reduced
glucose- and sulfonylurea-dependent insulin secretion. However, the response to K+ depolarization is intact in
Kir6.1-GOF mice compared with control islets. The presence of native Kir6.1 transcripts was demonstrated in
both human and wild-type mouse islets using quantitative real-time PCR. Together, these results implicate the
incorporation of native Kir6.1 subunits into pancreatic KATP channels and a contributory role for these subunits
in the control of insulin secretion.
Introduction

In the pancreatic β cell, ATP-sensitive K+ (KATP) channels play a critical role in coupling membrane excitability to glucose-stimulated insulin secretion, and
thereby maintaining blood glucose in a narrow range.
Gain-of-function (GOF) mutations in the pore-forming Kir6.2 subunit or in the regulatory sulfonylurea
receptor 1 (SUR1) subunit have been identified as the
commonest cause of human neonatal diabetes mellitus (NDM; Gloyn et al., 2004b; Vaxillaire et al., 2004;
Sperling, 2006; Hamilton-Shield, 2007; Polak and
Cavé, 2007). Normally, increased glucose metabolism
elevates intracellular [ATP]/[ADP] ratio inhibiting
KATP channels, leading to membrane depolarization,
opening of voltage-dependent Ca2+ channels, and an
increase in intracellular [Ca2+], which, in turn, triggers
insulin secretion (Nichols, 2006). Antidiabetic sulfonylurea drugs promote insulin secretion by binding to
the SUR1 subunit of the KATP channel, independently
of the metabolic state of the cell (Ashcroft and Gribble, 1999). Sulfonylurea drugs have been widely used
in type 2 diabetes treatment and, recently, successfully
used to treat NDM patients with KATP-GOF mutations
(Pearson et al., 2006).
There are two Kir6 subunit–encoding genes
(KCNJ8, Kir6.1 and KCNJ11, Kir6.2). Kir6.2 is a major

component of pancreatic β cell KATP channels: we
previously demonstrated development of profound
neonatal diabetes in mice constitutively expressing
Kir6.2-GOF mutations in pancreatic β cells (Koster et
al., 2000; Remedi et al., 2009). These mice rapidly develop severe diabetes followed by the development of
secondary consequences of systemic diabetes, including marked loss of insulin content and β cell mass
(Girard et al., 2009; Remedi et al., 2009; Wang et al.,
2014), consequences that are completely avoided by
maintenance of normoglycemia at disease onset (Remedi et al., 2009, 2011; Benninger et al., 2011) and
dramatically reversed by intensive insulin therapy
(Wang et al., 2014).
Kir6.1 was originally cloned from the pancreas
(Inagaki et al., 1995), but neither the presence of
Kir6.1-containing KATP channels in the β cell nor anycontribution to insulin secretion has been established.
Given the high sequence similarity between Kir6.1 and
Kir6.2, and based on the development of severe diabetes in Kir6.2-GOF mice (Girard et al., 2009; Remedi et
al., 2009), we hypothesized that pancreatic expression
of GOF mutations in the Kir6.1 subunit of the channel
would also decrease insulin secretion. To probe this, we
generated transgenic mice expressing Kir6.1 mutations
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under Cre-recombinase control to specifically express
the transgene in the tissue of interest. Single mutant
Kir6.1[G343D], double mutant Kir6.1[G343D,Q53R],
and WT Kir6.1 transgenic mice (Li et al., 2013) were
crossed with rat-insulin-promoter Cre mice (Rip-Cre
[Herrera, 2002]) to generate pancreatic β cell–specific
Rip-Kir6.1[GD], Rip-Kir6.1[GD,QR], and RipKir6.1[WT] mice, respectively. Single mutant RipKir6.1[GD] mice show glucose intolerance, and double
mutant Rip-Kir6.1[GD,QR] mice develop as severe diabetes as do Rip-Kir6.2-GOF transgenic mice. We also
expressed Kir6.1 mutants in bacterial artificial chromosomes (BACs) in order to express the transgene only in
tissues where the Kir6.1 gene is normally present. Strikingly, BAC-Kir6.1[GD] mice show similar glucose intolerance to Rip-Kir6.1[GD] mice. The results have
important implications for the molecular basis of pancreatic KATP channels and for the potential role of
KCNJ8 (Kir6.1) gene variants in insulin secretory control and the development of diabetes.

Human islets and study approval

Isolated cadaver-derived human islets were obtained
from the Integrated Islet Distribution Program (IIDP)
sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases and the JDRF-sponsored
Islets for Research Program at Washington University
(JDRF-31-2008-382). The IIDP uses only cadaver donors
that have consented to research. The Washington University Medical Center (WUMC) Human Studies Committee (HSC) Institutional Review Board (IRB)
approved all studies involving the use of isolated cadaver-derived human islets (approval number: 93-0068).
The IRB exempted the study from HIPAA compliance
based on the regulatory definition of human subject.
Review date: 7/8/2004; review committee: 08 MRCR.
Human islet donor data: four independent organ donors, two males and two females; mean age 35 yr, mean
purity 85.8%, and mean viability 92.9%.
Quantitative real-time PCR (qRT-PCR) analysis

Mouse islets were isolated and immediately processed
for RNA isolation. Upon arrival, human islets were collected by centrifugation, cleaned, and hand-selected in
CMRL media under a stereomicroscope (SMZ745 system; Nikon) and immediately processed for RNA isolation to perform qRT-PCR. Cellular RNA was isolated
using the RNeasy Mini kit (QIAGEN), and DNA was removed using DNase1 RNase-free solution (QIAGEN).
cDNA was prepared from RNA using the High Capacity
cDNA Reverse Transcription kit (Applied Biosystems),
and qRT-PCR was performed using StepOne software
2.3 and TaqMan primers (Applied Biosystems). Actin
was used as a reference gene.
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Inducible Kir6.1-GOF transgenes were generated by
subcloning WT, Kir6.1[Gly343Asp] (G343D), and
Kir6.1[Gly343Asp,Gln53Arg] (G343D,Q53R)-poly-A
cDNAs downstream of the CX-1 promoter in the
pBS-CX1-LEL vector (a gift from G. Owens, University of Virginia, Charlottesville, VA), which contains
the chicken β-actin (CX1) promoter, followed by
the eGFP coding region (including a stop codon),
flanked by two loxP sites, to create CX1-Kir6.1[WT],
CX1-Kir6.1[G343D], and CX1-Kir6.1[G343D,Q53R]
transgenic constructs (Li et al., 2013). 6–11 founder
mice carrying (1) Kir6.1[WT], Kir6.1[G343D], or
Kir6.1[G343D,Q53R] were generated and bred
to homogeneity by multiple (6×) backcrosses to
C57BL/6J mates as previously described (Li et al.,
2013). These mice were crossed with rat-insulin-promoter Cre (Rip-Cre) mice to generate pancreatic β
cell–specific Rip-Kir6.1[GD], Rip-Kir6.1[GD,QR],
and Rip-Kir6.1[WT] mice.
A mouse BAC containing the Kir6.1 genomic locus
(BAC ID# RP23-159E3) was used to generate the
Kir6.1[WT] and Kir6.1[G343D] BAC transgenes via
galK-based homologous recombination in bacteria.
Positive clones from the first round of recombineering were subjected to a second round of recombineering to remove the galK gene, leaving behind only the
desired mutations. Positive recombinants were identified via directional PCR, restriction digest, and sequencing. Mutant and WT BAC DNA were prepared
GEN maxi-prep, which was
using a modified QIA
dot dialyzed on 0.1 µM EMD Millipore filters using
BAC injection buffer. The Washington University
Transgenic Vectors Core generated the Kir6.1[WT]
and Kir6.1[G343D] BAC transgenes, and microinjection services were provided by the Washington
University Mouse Genetics Core. Kir6.1−/− (Kir6.1
knockout [Kir6.1KO]) mice, originally generated
by Miki et al. (2002), were obtained as a gift from
S. Seino (Kobe University Graduate School of Medicine, Kobe, Japan).
Animal study approval

All procedures complied with the standards for the care
and use of animal subjects as stated in the Guide for the
Care and Use of Laboratory Animals (National Institutes of Health publication No. 85-23, revised 1996).
Blood glucose

Tail blood was assayed for glucose content using a Glucometer Elite Xl meter (Bayer Corp). The limit of detection was 600 mg/dl, and glucose at or above this level
was recorded as 600 mg/dl but considered to be a lower
limit of the true value.
Kir6.1 in islet KATP channels | Remedi et al.
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Generation of CX1-Kir6.1[WT], CX1-Kir6.1[GD], CX1Kir6.1[GD,QR], BAC-Kir6.1[WT], and BAC-Kir6.1[GD]
transgenic mice
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Glucose tolerance test (GTT)

Intraperitoneal GTT was performed in 12-h fasted 7-wkold mice by injection of a bolus of glucose (1.5 g/kg
body weight). Blood was taken at different times and
assayed for glucose content as above.
Islet isolation

8-wk-old mice were anesthetized with 0.2 ml isoflurane
and killed by cervical dislocation. The bile duct was cannulated and perfused with Hank’s balanced salt solution (Sigma-Aldrich) containing collagenase (0.3 mg/
ml, Collagenase Type XI; Sigma-Aldrich). Pancreata
were removed and digested for 5 min at 37°C, hand
shaken, and washed three times in cold Hanks’ solution. Islets were isolated by hand under a dissecting
SMZ745 microscope, and pooled islets were maintained
overnight in CMRL-1066 (5.6 mM glucose) culture meCO) supplemented with 10% fetal calf
dium (GIB
serum, 100 U/ml penicillin, and 100 µg/ml streptomycin.
After overnight incubation in low glucose (5.6 mM)
CMRL-1066 medium, islets (10 per well in 12-well
plates) were preincubated in glucose-free CMRL-1066
plus 3 mM glucose and then incubated for 60 min at
37°C in CMRL-1066 plus different glucose concentrations, 1 µM glibenclamide, or 30 mM KCl, as indicated.
After the incubation period, the medium was removed
and assayed for insulin release. Insulin secretion was
measured using a Rat Insulin radioimmunoassay according to manufacturer’s procedure (RIA; EMD Millipore; Remedi et al., 2009). Plasma insulin was measured
using Singulex Erenna method (similar to insulin enzyme-linked immunosorbent assay) at the Core Laboratory for Clinical Studies, Washington University in St.
Louis. Experiments were repeated in triplicate.
Isolated islet fluorescence imaging

Freshly isolated islets from 8-wk-old mice were imaged
for eGFP, a reporter of transgene expression, using an
inverted florescent microscope (LSM 510 laser-scanning confocal microscope; ZEISS). Images were taken
with 20× objectives using the same settings for both control and transgenic islets.
86

Rb+ efflux experiments

Isolated islets were preincubated for 6 h with 86Rb+ (rubidium chloride 1.5 mCi/ml; GE Healthcare). Loaded
islets were placed in microcentrifuge tubes (30 per
group) and washed twice with RPMI-1640 medium at
37°C (Sigma-Aldrich). 86Rb+ efflux was assayed by replacing the bathing solution with Ringer’s solution with
metabolic inhibitor (MI), with or without 1 µM glibenclamide. MI solution contained 2.5 mg/ml oligomycin
and 1 mM 2-deoxyglucose, together with 10 mM tetraethylammonium to block voltage-gated K+ channels and
JGP Vol. 149, No. 1

Statistics

Data are presented as mean ± SEM. Differences among
groups were tested using unpaired t test to assess significance. Differences were assumed to be significant in
each case if P < 0.05, and nonsignificant differences are
not indicated in the figures.
R e s u lt s

Kir6.1 is expressed in mouse and human
pancreatic islets

Although Kir6.1 subunits are prominent components
of vascular KATP channels (Flagg et al., 2010), the cDNA
was originally cloned from pancreatic islets (Inagaki et
al., 1995), but there was little consideration of the presence of this subunit in insulin-secreting cells. The latter
studysuggest that Kir6.1 is naturally expressed in islets,
raising the possibility that Kir6.1 subunits might contribute to native islet KATP function. WT and Kir6.1KO
mouse islets were subjected to qRT-PCR. As predicted,
robust Kir6.1 signals, in addition to Kir6.2 signals, were
detected in mouse WT islets (Fig. 1 A), but there was no
Kir6.1 signal detectable (at up to 50 cycles) in Kir6.1KO
islets (Fig. 1 B), confirming the validity of the Kir6.1
signal in WT islets. Expression of Kir6.2 was not different between WT and Kir6.1KO islets (Fig. 1 B). Importantly, human islets obtained from cadaveric organ
donors also showed a robust Kir6.1 transcript level
(Fig. 1 C). Thus, the Kir6.1 subunit of the KATP channel
is natively present in both mouse and human pancreatic islets.
β cell expression of ATP-insensitive Kir6.1containing KATP channels

To study the effects of Kir6.1 subunits of the KATP channel in vivo, we have generated novel mice that express
either the Kir6.1 WT (Kir6.1[WT]) or a Kir6.1-GOF, single mutant G343D (Kir6.1[GD]) or double mutant
G343D/Q53R (Kir6.1[GD,QR]) transgenes under
Cre-recombinase control (Li et al., 2013). Global Cx1
Kir6.1[WT], Kir6.1[GD], and Kir6.1[GD,QR] mice express GFP fluorescence ubiquitously in the whole body,
but after tissue-specific Cre-recombination, these mice
lose fluorescence only in the tissue of interest (Li et al.,
2013). Specific expression in pancreatic β cells was
achieved by crossing Kir6.1 transgenic mice with RipCre mice. Fig. 2 shows marked loss of fluorescence in
77
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10 µM nifedipine to block Ca2+ entry. The other solutions were different glucose concentrations (1, 7, and
20 mM glucose). The bathing solution was replaced
with fresh solution every 5 min over a 50-min period
and counted in a scintillation counter. 86Rb efflux in the
presence of glucose and drugs were fit by a single exponential, in which the rate constant (k) is proportional to
the K+ (Rb+)-conductance in the islet membranes.
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pancreatic islets from double transgenic Rip-Kir6.1[WT]
(A), Rip-Kir6.1[GD] (B), and Rip-Kir6.1[GD,QR] (C; as
an indication of transgene expression), compared with
bright fluorescent islets from single Kir6.1[WT],
Kir6.1[GD], and Kir6.1[GD,QR] transgenic mice (lacking recombination and absence of transgene expression). Littermate control mice in all experiments below
include pooled WT, single transgenic Rip-Cre, and single transgenic Kir6.1[GD] or Kir6.1 [GD,QR] mice. In
each case, no significant differences were found between these genotypes when independently tested.
Diabetes in Kir6.1-GOF mutant mice

GOF mutations in the Kir6.1 subunit of the KATP channel result in either glucose intolerance (RipKir6.1[GD]) or frank diabetes (Rip-Kir6.1[GD,QR]),
78

mimicking the consequences of weak or more significant expression of Kir6.2-GOF transgenes (Koster et
al., 2000, 2005; Remedi et al., 2009). 7-wk-old double
transgenic Rip-Kir6.1[GD] mice showed higher fed
glucose than littermate control mice (Fig. 2 B). They
also demonstrate increased fasting blood glucose and a
mildly impaired glucose tolerance, accompanied by reduced circulating plasma insulin after glucose challenge with respect to control littermates (Fig. 3 B).
Importantly, however, 2 out of 10 Rip-Kir6.1[GD] mice
showed diabetes with dramatically high fasting blood
glucose levels and a marked impairment of glucose tolerance (Fig. 2 B). Strikingly, all Rip-Kir6.1[GD,QR]
mice developed severe diabetes (Fig. 2 C) with markedly impaired glucose tolerance, as the result of significantly reduced plasma insulin levels in response to
Kir6.1 in islet KATP channels | Remedi et al.
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Figure 1. Kir6.1 transcript is present in primary human and mouse islets. qRT-PCR in mouse and human islets. (A and B) Representative traces of transcript amplification versus cycle number from mouse islets. (A) Insulin is represented in red, Kir6.2 in green,
and Kir6.1 in blue. Actin was used as housekeeping gene and is shown in orange. Same color lines are duplicates from the same
sample. (B) Comparative amplification traces for Kir6.2 (green) and Kir6.1 (blue) genes in WT and Kir6.1KO islets (n = 5 mice of each
genotype, each sample was run in duplicates). Kir6.2 transcripts are present at similar levels in both WT and Kir6.1KO islets, but
Kir6.1 transcript is only detected in WT islets and not in Kir6.1KO islets. (C) Each color represents traces for Kir6.1 transcript and
the corresponding actin transcript in islets from independent human cadaveric organ donors. (D) Mean crossing threshold (Ct) for
transcripts from mouse and human islets. Data represent mean ± SEM, n = 4 independent batches of human islets and n = 5 mice
from each genotype. Samples were run in duplicates.
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Figure 2. Increased blood glucose in Kir6.1-GOF
mice. (A–C, left) Representative intrinsic GFP fluorescence in freshly isolated islets from transgenic mice.
High fluorescence in transgenic islets indicates the
presence of the Kir6.1 transgene (Kir6.1[x], Control),
and loss of fluorescence in transgenic β cells within islets after Cre-recombination (Rip-Kir6.1[x]) indicates
actual expression of the transgene specifically in these
cells. Bars, 10 µm. (right) Fed blood glucose over time
after weaning in Rip-Kir6.1[WT] (A, black), single mutant Rip-Kir6.1[GD] (B, green), and double mutant
Rip-Kir6.1[GD,QR] (C, red) with respect to their control
littermates (white). Data represent mean ± SEM, n =
8–10 animals in each group. Significant differences (*, P
< 0.05) between transgenic and control littermate mice
are indicated (t test).

Downloaded from on January 4, 2017

glucose challenge (Fig. 3 C). Importantly, however, and
as expected, overexpression of WT Kir6.1 subunits in
Rip-Kir6.1[WT] mice did not result in increased blood
glucose or glucose intolerance (Figs. 2 A and 3A), suggesting that impaired glucose tolerance and diabetes
are promoted by Kir6.1-GOF and are not an artifactual
consequence of overexpressed transgenic protein
levels per se.
We have also generated BAC Kir6.1 transgenic (BACKir6.1[GD]) and WT (BAC-Kir6.1[WT]) mice (see Materials and methods). Because the BAC constructs are
expected to contain the native regulatory elements of
the Kir6.1 gene, with no exogenous promoter, the transgene should be expressed under native promoter control, and hence only in tissues where the Kir6.1 subunit
JGP Vol. 149, No. 1

is normally present. Strikingly, BAC-Kir6.1[GD] mice
show higher blood glucose levels, reduced circulating
insulin in fed conditions (Fig. 4 A), and impaired glucose tolerance with reduced plasma insulin at 30 min,
compared with BAC-Kir6.1[WT] mice (Fig. 4 B). The
similar phenotype of BAC-Kir6.1[GD] mice to RipKir6.1[GD] mice implicates native Kir6.1 in controlling
glucose tolerance and, as shown below, most likely by
regulating β cell secretion directly. Given the likely low
level of Kir6.1 in the β cell, under normal conditions,
WT Kir6.1 is unlikely to play a major role, and we detected no significant effects of Kir6.1KO on blood glucose (Kir6.1KO: 108 ± 2.02 mg/dl and WT: 119 ± 2.59
mg/dl), glucose tolerance, or KATP conductance assessed by Rb efflux (not depicted).
79
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Figure 3. Glucose tolerance in
Kir6.1 transgenic mice. (A–C) GTT on
12-h fasted (left) and plasma insulin
(right) in Rip-Kir6.1[WT] (A, black), RipKir6.1[GD] (B, green), and Rip-Kir6.1[GD,QR] (C, red) and control littermates
at 7 wk of age. Blood glucose concentration versus time after injection of
1.5 g/kg glucose. Plasma insulin was
determined in fasted mice (time 0) and
30 min after glucose challenge during
GTT. Data represent mean ± SEM, n =
8–10 animals in each group. For RipKir6.1[GD], 2 of 10 animals, with fasting
blood glucose >300 mg/dl, are shown
individually (dashed line), and the remaining 8 of 10 animals, with fasting
blood glucose <200 mg/dl, are shown
as mean data (solid line). Significant
differences (*, P < 0.05) between transgenic and control littermate mice are
indicated (t test).

Downloaded from on January 4, 2017

Kir6.1-GOF mouse islets show decreased
responsivity to glucose challenge but
maintained KCl response

Consistent with hyperglycemia in BAC-Kir6.1[GD] mice
shown above, there was also a modest but significant
reduction in glucose-dependent insulin secretion from
isolated BAC-Kir6.1[GD] islets, with respect to controls
(Fig. 5). Importantly, however, BAC-Kir6.1[GD] still
responded to glibenclamide, although with an smaller
response, and responded with similar maximal secretion in response to K+ depolarization (KCl; Fig. 5), indicating no marked impairment of secretory processes
downstream of the electrical signal. As expected, BACKir6.1[WT] mice showed similar glucose- and glibenclamide-dependent secretion to control littermate
mice (Fig. 5).
80

Kir6.1-GOF islets exhibit a reduction in total KATP
channel density but sensitivity to glibenclamide drugs

K conductance in intact BAC-Kir6.1[WT] and BACKir6.1[GD] transgenic was assessed by 86Rb+ efflux in
the presence of different [glucose] and glibenclamide.
Fig. 6 A shows representative sample fluxes from both
genotypes. Fluxes were fit by single exponentials and
reciprocal rate constants (normalized to 1 mM glucose)
are plotted in Fig. 6 B. In BAC-Kir6.1[WT] islets, the
flux is glucose sensitive, being almost completely reduced to basal (i.e., flux in glibenclamide) in the presence of 20 mM glucose. In contrast, the BAC-Kir6.1[GD]
flux is markedly less glucose sensitive, with substantial
glibenclamide-sensitive (i.e., KATP-dependent) flux still
present even at 20 mM glucose (Fig. 6 B). Interestingly,
the absolute maximum rate constant (in 1 mM glucose)
Kir6.1 in islet KATP channels | Remedi et al.
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Figure 4. Fed blood glucose and glucose tolerance in BAC-Kir6.1 mice. (A)
Fed blood glucose (left) and plasma
insulin (right) in BAC-Kir6.1[WT] (blue),
BAC-Kir6.1[GD] (pink), and control
littermate (white) mice. (B) Glucose
(left) and insulin levels (right) at time 0
(fasting) and 30 min after glucose challenge in BAC-Kir6.1[WT] (blue), BACKir6.1[GD] (pink), and control littermate
(white) mice. Data represent mean ±
SEM, n = 10–15 animals in each group.
Significant differences (*, P < 0.05)
between transgenic and control littermate mice under the same condition
and (#, P < 0.05) on the same genotype
mice under different conditions are
indicated. Nonsignificant differences
are not indicated.

Di s c u s s i o n

ing order according to magnitude of expression, i.e.,
insulin was ranked 1; Segerstolpe et al., 2016). Together,
these studies highlight the presence of Kir6.1 in pancreatic β cells and raise the exciting possibility that alterations in Kir6.1 expression or channel properties could
affect insulin secretion and thereby play a modulatory
role in human diabetes.

Kir6.1-containing channels are present in both human
and mouse islets: Implications for human diabetes

Diabetes induced by GOF mutation in the Kir6.1
subunit of the KATP channel

Although Kir6.1 subunits (encoded by KCNJ8) are prominent components of vascular KATP channels (Flagg et al.,
2010), the Kir6.1 cDNA was originally cloned from pancreatic islets (Inagaki et al., 1995), yet there has been little subsequent consideration of any role or even the
likely presence of this subunit in insulin-secreting cells.
Our expression analysis shows that Kir6.1 transcript is
clearly present in both human and mouse islets (Fig. 1)
and, importantly, that there is no Kir6.1 transcript detected in Kir6.1KO mouse islets and no effect of Kir6.1
deletion on Kir6.2 transcript levels (Fig. 1). Other experiments (supplementary data in Pagliuca et al. [2014])
have also found KCNJ8 gene expression in human β cells
isolated from cadaveric donors and in β cells generated
from human pluripotent stem cells. Furthermore, transcriptome data from 10 human cadaveric organ donors
show that KCNJ8 (Kir6.1, ranked 5,410) was second only
to KCNJ11 (Kir6.2, ranked 3,486) as the highest expressed Kir subunit in β cells (genes ranked in descendJGP Vol. 149, No. 1

In the pancreatic β cell, KATP channels are the critical link
between glucose metabolism and insulin secretion, highlighted by the fact that GOF mutations in the pore-forming Kir6.2 and regulatory SUR1 subunits of the KATP
channel (KATP-GOF) are the main cause of human NDM
(Gloyn et al., 2004a,b; Vaxillaire et al., 2004; Massa et al.,
2005). Mice expressing Kir6.2-GOF mutations specifically in pancreatic β cells reiterate key features of NDM
(Koster et al., 2000; Girard et al., 2009; Remedi et al.,
2009). Here, we have shown that pancreatic expression
of a severely ATP-insensitive Kir6.1 mutation in
Rip-Ki6.1[GD,QR] mice also results in reduced circulating plasma insulin and development of severe diabetes,
whereas expression of a mildly ATP-insensitive mutation
in Rip-Kir6.1[GD] mice leads to development of glucose
intolerance, comparable with the phenotypes of strong
and mild GOF mutations in Kir6.2 in mice and humans
(Koster et al., 2000, 2006; Gloyn et al., 2004b; Flanagan et
al., 2007; Remedi et al., 2009, 2011; Villareal et al., 2009).
81
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was slightly lower in BAC-Kir6.1[GD] islets (0.029 ±
0.010 min−1) than in control islets (0.042 ± 0.004 min−1),
which may reflect reduced maximal KATP conductance
as a result of lower single channel current in Kir6.1-containing channel pores (Nichols, 2006).
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Our data show that deliberate expression of Kir6.1GOF mutations in β cells can result in their ready incorporation into functional β cell KATP channels and hence
in the modulation of insulin secretion. One potential
caveat is that transgenic expression of mutant subunit
proteins may result in gross islet abnormalities, but the
fact that no significant differences were found between
Rip-Kir6.1[WT] mice and littermate control mice (Figs.
2 A and 3A) suggests no major abnormalities as a result
of transgene overexpression per se. More importantly,
BAC-Kir6.1-GOF transgenic mice (but not BACKir6.1[WT] transgenic mice), which express the transgene under control of the native promoter, also show
higher glucose levels and reduced circulating plasma
insulin in fed conditions (Fig. 4 A). BAC-Kir6.1-GOF
show glucose intolerance with decreased insulin secretion 30 min after glucose challenge (Fig. 4 B) and a specific reduction in glucose-sensitive insulin secretion in
vitro (Fig. 5). The overall KATP conductance in BACKir6.1-GOF transgenic islets exhibits reduced glucose
sensitivity, with substantial glibenclamide-sensitive Rb
flux still present at high (20 mM) [glucose] (Fig. 6).
These results imply that not only are Kir6.1 subunits
normally expressed in the islet but that GOF mutations
can reduce the glucose dependence of KATP conductance and hence of insulin secretion.
Diabetic mice and patients with KATP-GOF mutations
respond to sulfonylurea drugs

The high sensitivity of Kir6.2/SUR1 channels to sulfonylurea inhibition has led to a dramatic change in
therapy for NDM, with most patients successfully trans82
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Figure 5. Impaired glucose-dependent insulin secretion
in BAC-Kir6.1[GD] transgenic mice. Glucose-dependent insulin secretion on isolated islets from BAC-Kir6.1[GD] and
BAC-Kir6.1[WT] mice. Batches of 10 islets were statically preincubated in low glucose and then incubated in various glucose
concentrations, or in glibenclamide, or in KCl for 1 h. Data represent mean ± SEM, n = 4–5 mice in each group. Significant
differences (*, P < 0.05) between transgenic and control littermates under the same condition are indicated (t test).

Figure 6. Reduced glucose sensitivity of KATP conductance in
Kir6.1-GOF islets. (A) Glucose- and glibenclamide-dependent
Rb+ effluxes from BAC-Kir6.1[WT] (blue) and BAC-Kir6.1[GD]
(pink) islets. (B) Rate constant for Rb+ efflux at each condition
(ktest), normalized to rate constant in 1 mM glucose (k1G), in BACKir6.1[WT] and BAC-Kir6.1[GD] islets. Data represent mean ±
SEM, n = 4 mice (n > 50 islets per sample) in each group.

ferring from injected insulin therapy to sulfonylurea
tablets (Hattersley and Ashcroft, 2005; Pearson et al.,
2006; Masia et al., 2007; Wambach et al., 2010) or even
being initiated on sulfonylurea therapy (Wambach et
al., 2010; Marshall et al., 2015). However, many Kir6.2GOF mutations also exhibit reduced sensitivity to sulfonylureas (Koster et al., 2005), which may contribute
to the generally observed requirement for relatively
high doses of sulfonylureas in treatment of NDM patients (Hattersley and Ashcroft, 2005; Pearson et al.,
2006). The involvement of Kir6.1 subunits in β cell
KATP channels has potentially important implications
for KATP pharmacologies in the treatment of diabetes
and the possibility that isoform-specific blockers of
Kir6.1 in islet KATP channels | Remedi et al.
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these channels (Wellman et al., 1999) may need to be
considered in the future. Although no mutations in
the Kir6.1-encoding gene (KCNJ8) located on chromosome 12p12 have yet been identified in diabetic patients, multiple studies have suggested linkage to
diabetes mapping to chromosome 12p (Ng et al., 2004;
Wiltshire et al., 2004). Further studies will be necessary
to confirm any linkage between Kir6.1 and glucose intolerance or diabetes.
A c k n o w l e d gm e n t s
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